Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
Open Access
- 29 August 2018
- journal article
- research article
- Published by Wiley in Advanced Therapeutics
- Vol. 1 (6)
Abstract
Combination chemotherapy is a cornerstone of cancer treatment. Optimizing its effectiveness requires dose‐ and time‐dependent regulation of drug synergy. In this report, CURATE.AI, an artificial intelligence platform, is used to prospectively guide the dosing of a bromodomain inhibitor (ZEN‐3694) and enzalutamide administered in combination to a patient with metastatic castration‐resistant prostate cancer to reduce serum prostate‐specific antigen (PSA) levels. CURATE.AI successfully identifies substantial ZEN‐3694 and enzalutamide dose adjustments, increasing both treatment efficacy and tolerance. CURATE.AI analysis also confirms that the patient's durable response is mediated by ZEN‐3694 inclusion in the regimen. Due to CURATE.AI‐enhanced efficacy and safety, the patient was able to continue with the combination regimen, resulting in a durable response and no disease progression based on CURATE.AI‐sustained control over PSA levels and reduced lesion size.Keywords
Funding Information
- V Foundation for Cancer Research
- Wallace H. Coulter Foundation
This publication has 31 references indexed in Scilit:
- Genomics and Drug ResponseNew England Journal of Medicine, 2011
- Selective inhibition of BET bromodomainsNature, 2010
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- Cancer systems biology: a network modeling perspectiveCarcinogenesis, 2009
- Endpoints for Assessing Drug Activity in Clinical TrialsThe Oncologist, 2008
- Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithmProceedings of the National Academy of Sciences, 2008
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Response Rate as an Endpoint in Clinical TrialsJNCI: Journal of the National Cancer Institute, 2007
- Personalized medicine: revolutionizing drug discovery and patient careTrends in Biotechnology, 2001